- ISIN
- BMG5269C1010
- CUSIP
- G5269C101
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 24, 2018
Highlights
- Market Cap
- $3.94B
- Enterprise Value
- $3.77B
- EPS (TTM)
- $0.92
- PE Ratio
- 51.96
- PEG Ratio
- 0.50
- Total Revenue (TTM)
- $754.05M
- Gross Profit (TTM)
- $294.06M
- EBITDA (TTM)
- $101.06M
- Year Range
- $26.27 - $59.87
- Target Price
- $61.50
- ROA (TTM)
- 8.85%
- ROE (TTM)
- 12.06%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
KNSA Performance Chart
Kiniksa Pharmaceuticals, Ltd. (KNSA) is up 16.0% since the beginning of the year. At $48 per share, KNSA is trading 20.1% below its 52-week high of $60. Investors who bought $1,000 worth of KNSA shares 5 years ago would now be looking at an investment worth $3,588.
Loading charts...
Returns By Period
Kiniksa Pharmaceuticals, Ltd. (KNSA) has returned 16.00% so far this year and 64.38% over the past 12 months.
Kiniksa Pharmaceuticals, Ltd.
- 1D
- 1.98%
- 1M
- -16.96%
- YTD
- 16.00%
- 6M
- 17.89%
- 1Y
- 64.38%
- 3Y*
- 48.51%
- 5Y*
- 29.11%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
KNSA Monthly Returns History
Based on dividend-adjusted daily data since May 24, 2018, KNSA's average daily return is +0.12%, while the average monthly return is +2.25%. At this rate, an investment would double in approximately 2.6 years.
Historically, 53% of months were positive and 47% were negative. The best month was Aug 2018 with a return of +57.5%, while the worst month was Jan 2019 at -37.7%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 5 months.
On a daily basis, KNSA closed higher 50% of trading days. The best single day was Jul 25, 2023 with a return of +30.4%, while the worst single day was Mar 16, 2020 at -24.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 6.47% | 1.30% | 8.23% | 11.69% | -10.04% | -1.10% | 16.00% | ||||||
| 2025 | -0.91% | 3.47% | 9.52% | 21.43% | 1.45% | 1.13% | 9.36% | 10.67% | 15.95% | -4.69% | 14.89% | -2.99% | 108.54% |
| 2024 | 0.51% | 19.91% | -6.67% | -5.12% | 1.55% | -1.79% | 42.47% | 0.53% | -6.54% | -9.60% | -2.26% | -10.42% | 12.77% |
| 2023 | -3.47% | -11.07% | -16.33% | -0.09% | 28.93% | 1.59% | 33.81% | -8.55% | 0.81% | -12.20% | 6.03% | 8.47% | 17.09% |
| 2022 | -4.59% | -8.82% | -2.93% | -6.14% | -17.90% | 26.50% | 2.27% | 18.26% | 9.56% | -11.06% | 47.37% | -10.99% | 27.27% |
| 2021 | 11.43% | 4.47% | -10.01% | -11.08% | -17.19% | 2.20% | 10.05% | -17.94% | -9.46% | -8.78% | 11.84% | 1.29% | -33.39% |
Benchmark Metrics
Kiniksa Pharmaceuticals, Ltd. has an annualized alpha of 19.26%, beta of 0.92, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since May 25, 2018.
- This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (34.29%) than losses (6.37%) - typical of diversified or defensive assets.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 19.26%
- Beta
- 0.92
- R²
- 0.08
- Upside Capture
- 34.29%
- Downside Capture
- 6.37%
Return for Risk
Risk / Return Rank
KNSA ranks 83 for risk / return — in the top 83% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Kiniksa Pharmaceuticals, Ltd. (KNSA) and compare them to S&P 500 Index.
| KNSA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.76 | ||
| Sortino ratioReturn per unit of downside risk | -0.69 | ||
| Omega ratioGain probability vs. loss probability | 1.30 | 1.41 | -0.11 |
| Calmar ratioReturn relative to maximum drawdown | 3.06 | 2.93 | +0.14 |
| Martin ratioReturn relative to average drawdown | 11.39 | 13.52 | -2.13 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Kiniksa Pharmaceuticals, Ltd.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Kiniksa Pharmaceuticals, Ltd. was 83.06%, occurring on Oct 18, 2019. Recovery took 1453 trading sessions.
The current Kiniksa Pharmaceuticals, Ltd. drawdown is 19.55%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2019 bear market2019 | -83.06%Oct 2019 | 1y 27d | 5y 9mo | 6y 10moSep 2018 - Aug 2025 |
2018 bear market2018 | -34.99%Jul 2018 | 1mo 6d | 1mo 3d | 2mo 9dJun 2018 - Aug 2018 |
2026 bear market2026 | -21.12%Jun 2026 | 20d | — | 22d 6hMay 2026 - now |
2026 correction2026 | -14.33%Apr 2026 | 14d | 7d | 21dApr 2026 - Apr 2026 |
Rate-hike selloffLate 2018 | -13.47%Sep 2018 | 2d | 6d | 8dSep 2018 - Sep 2018 |
Drawdown Indicators
| KNSA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.06% | -56.78% | -26.28% |
Max Drawdown (1Y)Largest decline over 1 year | -21.12% | -9.10% | -12.02% |
Max Drawdown (3Y)Largest decline over 3 years | -34.14% | -18.90% | -15.24% |
Max Drawdown (5Y)Largest decline over 5 years | -53.17% | -25.43% | -27.74% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -19.55% | -0.74% | -18.81% |
Average DrawdownAverage peak-to-trough decline | -40.26% | -10.72% | -29.54% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.67% | 1.97% | +3.70% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Kiniksa Pharmaceuticals, Ltd. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Kiniksa Pharmaceuticals, Ltd. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for KNSA, comparing it with other companies in the Biotechnology industry. Currently, KNSA has a P/E ratio of 52.0. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for KNSA compared to other companies in the Biotechnology industry. KNSA currently has a PEG ratio of 0.5. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for KNSA relative to other companies in the Biotechnology industry. Currently, KNSA has a P/S ratio of 5.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for KNSA in comparison with other companies in the Biotechnology industry. Currently, KNSA has a P/B value of 6.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with KNSA
Add Kiniksa Pharmaceuticals, Ltd. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with KNSA